Summary
62 / 100 · Bulios Score
What speaks for it
- Out of every 100 JPY of revenue, 24 JPY is left as net profit.
- Analysts expect revenue to grow by 12% this fiscal year.
What to watch
- Revenue fell by 11% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 6.1 JPY for 1 JPY of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue fell by 3.7% a year over 5 years. Over the last 3 years it fell by 11% a year. For the next fiscal year analysts expect revenue to grow by 12%. Earnings per share fell by 25% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 JPY of revenue goes
- Cost of sales 45 JPY
- Research and development 10.0 JPY
- Sales and administration 35 JPY
- Taxes and other -14 JPY
- Net profit 24 JPY
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 JPY
Out of every 100 JPY of revenue, 24 JPY is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.6 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 0
- Hold 1
- Sell 0
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.